$60,000 of HCA HEALTHCARE lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Hospital outpatient issues. Issues related to Medicare payment policies, Medicaid waivers and physician owned hospitals. Hospital Outpatient issues. Medicaid directed payment programs. Medicaid reform. PL 119-21, An act to provide for reconciliation pursuant to title II of H. Res. Con. 14. Issues related to enhanced premium tax credits. PL 119-21, An act to provide for reconciliation pursuant to title II of H. Res. Con. 14."
You can find more data on corporate lobbying on Quiver Quantitative.
HCA Congressional Stock Trading
Members of Congress have traded $HCA stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $HCA stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/19 and 1 sale worth up to $15,000 on 09/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
HCA Insider Trading Activity
HCA insiders have traded $HCA stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $HCA stock by insiders over the last 6 months:
- MICHAEL R MCALEVEY (EVP & Chief Legal & Admin Off.) sold 3,892 shares for an estimated $1,843,990
- MICHAEL S. CUFFE (EVP and Chief Clinical Officer) sold 3,836 shares for an estimated $1,606,670
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HCA Hedge Fund Activity
We have seen 574 institutional investors add shares of HCA stock to their portfolio, and 576 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,465,455 shares (+74.5%) to their portfolio in Q3 2025, for an estimated $624,576,921
- LONGVIEW PARTNERS (GUERNSEY) LTD removed 1,287,869 shares (-82.4%) from their portfolio in Q3 2025, for an estimated $548,889,767
- PACER ADVISORS, INC. added 896,437 shares (+6115.3%) to their portfolio in Q3 2025, for an estimated $382,061,449
- PRICE T ROWE ASSOCIATES INC /MD/ removed 813,787 shares (-59.6%) from their portfolio in Q3 2025, for an estimated $346,836,019
- VANGUARD GROUP INC removed 580,889 shares (-3.8%) from their portfolio in Q3 2025, for an estimated $247,574,891
- VIKING GLOBAL INVESTORS LP removed 491,550 shares (-26.3%) from their portfolio in Q3 2025, for an estimated $209,498,610
- BLACKROCK, INC. removed 483,554 shares (-3.7%) from their portfolio in Q3 2025, for an estimated $206,090,714
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HCA Analyst Ratings
Wall Street analysts have issued reports on $HCA in the last several months. We have seen 11 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Underweight" rating on 12/15/2025
- Truist Securities issued a "Buy" rating on 10/27/2025
- Oppenheimer issued a "Outperform" rating on 10/27/2025
- Mizuho issued a "Outperform" rating on 10/27/2025
- Keybanc issued a "Overweight" rating on 10/27/2025
- TD Cowen issued a "Buy" rating on 10/27/2025
- RBC Capital issued a "Outperform" rating on 10/27/2025
To track analyst ratings and price targets for HCA, check out Quiver Quantitative's $HCA forecast page.
HCA Price Targets
Multiple analysts have issued price targets for $HCA recently. We have seen 17 analysts offer price targets for $HCA in the last 6 months, with a median target of $490.0.
Here are some recent targets:
- Stephen Baxter from Wells Fargo set a target price of $452.0 on 01/07/2026
- Ann Hynes from Mizuho set a target price of $520.0 on 12/18/2025
- Craig Hettenbach from Morgan Stanley set a target price of $425.0 on 12/15/2025
- Brian Tanquilut from Jefferies set a target price of $525.0 on 10/28/2025
- Ben Hendrix from RBC Capital set a target price of $482.0 on 10/27/2025
- Andrew Mok from Barclays set a target price of $494.0 on 10/27/2025
- Raj Kumar from Stephens & Co. set a target price of $500.0 on 10/27/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
